A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Early-Line Treatment in Subjects with Multiple Myeloma

Trial Identifier:	D831EC00001
Sponsor:	AstraZeneca
Start Date:	August 2025
Primary Completion Date:	June 2028
Study Completion Date:	June 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
United States, NY	New York, NY, United States, 10016

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.